- Open
- 765.00
- High
- 770.00
- Low
- 750.00
- Close
- 750.25
- Change
- -15.00 (-1.96%)
- Volume
- 61,462
| 17 Nov 2026 | 07:00:04 | Adaptix signs MOU with IBEX on bone health |
| 27 Oct 2026 | 09:29:01 | Holding(s) in Company |
| 1 Oct 2026 | 15:31:40 | Holding(s) in Company |
| 30 Sept 2026 | 07:01:00 | Acquisition of Nuclear IP Assets in the USA |
| 11 Nov 2026 | Annual Report and Accounts (to 2026-05-31) | |
| 20 Oct 2025 | Annual Report and Accounts (to 2025-05-31) | |
| 25 Feb 2025 | Annual Report and Accounts (to 2024-05-31) |
Avingtrans plc operates as an engineering company focused on acquiring and developing underperforming businesses in niche markets, particularly those in highly regulated sectors. The company employs a strategy known as Pinpoint-Invest-Exit (PIE), which aims to create value through operational excellence and consolidation opportunities. Avingtrans serves various end-markets, including aerospace, energy, and medical sectors, and maintains a commitment to ethical practices, safety, and environmental responsibility across its operations.
| 17 Nov 2026 | 07:00:04 | Adaptix signs MOU with IBEX on bone health |
| 27 Oct 2026 | 09:29:01 | Holding(s) in Company |
| 1 Oct 2026 | 15:31:40 | Holding(s) in Company |
| 30 Sept 2026 | 07:01:00 | Acquisition of Nuclear IP Assets in the USA |
| 11 Nov 2026 | Annual Report and Accounts (to 2026-05-31) | |
| 20 Oct 2025 | Annual Report and Accounts (to 2025-05-31) | |
| 25 Feb 2025 | Annual Report and Accounts (to 2024-05-31) |
Avingtrans plc operates as an engineering company focused on acquiring and developing underperforming businesses in niche markets, particularly those in highly regulated sectors. The company employs a strategy known as Pinpoint-Invest-Exit (PIE), which aims to create value through operational excellence and consolidation opportunities. Avingtrans serves various end-markets, including aerospace, energy, and medical sectors, and maintains a commitment to ethical practices, safety, and environmental responsibility across its operations.
| 30 Sept 2026 |
| 07:00:06 |
| Preliminary results for the year ended 31 May 2026 |
| 14 Oct 2026 |
| Avingtrans CEO Steve McQuillan on record revenue, nuclear demand and medical imaging progress |
| 5 Oct 2026 | Avingtrans plc: Record £163m Revenue, 90% Order Cover and Adaptix Nears Commercial Breakthrough |
| 30 Sept 2026 | Avingtrans reports record revenue and strong profit growth as AI and nuclear demand builds |
| 30 Sept 2026 | Avingtrans acquires US nuclear specialist Joseph Oat for $2.5m |
| 22 Sept 2026 | Avingtrans: the Finals next week could see its shares blast above analysts’ expectations |
| 10 Jul 2026 | AIM movers: Impax Asset Management asset improvement and Avingtrans raises cash for nuclear growth |
| 30 Sept 2026 |
| 07:00:06 |
| Preliminary results for the year ended 31 May 2026 |
| 14 Oct 2026 |
| Avingtrans CEO Steve McQuillan on record revenue, nuclear demand and medical imaging progress |
| 5 Oct 2026 | Avingtrans plc: Record £163m Revenue, 90% Order Cover and Adaptix Nears Commercial Breakthrough |
| 30 Sept 2026 | Avingtrans reports record revenue and strong profit growth as AI and nuclear demand builds |
| 30 Sept 2026 | Avingtrans acquires US nuclear specialist Joseph Oat for $2.5m |
| 22 Sept 2026 | Avingtrans: the Finals next week could see its shares blast above analysts’ expectations |
| 10 Jul 2026 | AIM movers: Impax Asset Management asset improvement and Avingtrans raises cash for nuclear growth |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £1.05bn | -0.3% | |
| £387m | +0.1% | |
AVGAvingtrans plc | £277m | +0.5% |
| £202m | +0.1% | |
| £12m | -0.0% | |
| £6m | -0.3% |
| Issuer | Mkt cap | 1Y |
|---|---|---|
| £1.05bn | -0.3% | |
| £387m | +0.1% | |
AVGAvingtrans plc | £277m | +0.5% |
| £202m | +0.1% | |
| £12m | -0.0% | |
| £6m | -0.3% |